Expression of AC133 on Acute ALL and AML
| . | CD34+ . | CD34− . |
|---|---|---|
| AC133++ (third decade) | Case 1 AML, M4 | None |
| Case 2 AML, M5 | ||
| Case 3 AML, M4 | ||
| AC133+ (second decade) | Case 4 ALL | None |
| Case 5 AML | ||
| Case 6 ALL | ||
| Case 7 ALL | ||
| AC133− | Case 8 ALL | Case 12 AML |
| Case 9 AML | ||
| Case 10 ALL | ||
| Case 11 ALL |
| . | CD34+ . | CD34− . |
|---|---|---|
| AC133++ (third decade) | Case 1 AML, M4 | None |
| Case 2 AML, M5 | ||
| Case 3 AML, M4 | ||
| AC133+ (second decade) | Case 4 ALL | None |
| Case 5 AML | ||
| Case 6 ALL | ||
| Case 7 ALL | ||
| AC133− | Case 8 ALL | Case 12 AML |
| Case 9 AML | ||
| Case 10 ALL | ||
| Case 11 ALL |
Twelve samples of bone marrow from patients with acute leukemia were obtained by bone marrow aspiration. Expression of AC133 and CD34 was determined by multiparameter flow cytometry using directly conjugated MoAbs. Eleven of 12 acute leukemias expressed CD34 and were subclassified according to whether they expressed bright levels of AC133 (between the second and third decade of fluorescence intensity); dim levels of AC133 (between the first and second decade of fluorescence), or no AC133 (between the second and third decade of fluorescence), or no AC133 (fluorescence was limited to the first decade of fluorescence intensity). The single CD34− leukemia (case no. 12) lacked AC133 expression. Only myelomonocytic acute leukemia (FAB M4 or M5) expressed the highest level of AC133 (cases no. 1, 2, and 3).